Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.

@article{Buas2016IdentificationON,
  title={Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.},
  author={Matthew F. Buas and Haiwei Gu and Danijel Djukovic and Jiangjiang Zhu and Charles W. Drescher and Nicole D. Urban and Daniel Raftery and Christopher I. Li},
  journal={Gynecologic oncology},
  year={2016},
  volume={140 1},
  pages={138-44}
}
OBJECTIVE Serous ovarian carcinoma (OC) represents a leading cause of cancer-related death among U.S. women. Non-invasive tools have recently emerged for discriminating benign from malignant ovarian masses, but evaluation remains ongoing, without widespread implementation. In the last decade, metabolomics has matured into a new avenue for cancer biomarker development. Here, we sought to identify novel plasma metabolite biomarkers to distinguish serous ovarian carcinoma and benign serous ovarian… CONTINUE READING